Brain demyelination in children with Crohn’s disease
Authors:
A. Šuláková 1,2; J. Horáček 3; V. Doležilová 4; O. Škopková 2
Authors place of work:
Katedra interních oborů, LF Ostravská univerzita, Ostrava
vedoucí katedry MUDr. I. Valkovský
1; Klinika dětského lékařství, FN Ostrava
přednosta doc. MUDr. M. Hladík, Ph. D.
2; Ústav patologické anatomie a soudního lékařství, LF Ostravská univerzita, Ostrava
vedoucí katedry prof. MUDr. J. Mačák, CSc.
3; Radiodiagnostický ústav, FN Ostrava
přednosta MUDr. A. Jahodová
4
Published in the journal:
Čes-slov Pediat 2012; 67 (Suppl 1): 29-35.
Category:
Original Papers
Summary
Background:
Crohn’s disease and ulcerative colitis are inflammatory bowel disease (IBD) with chronic relapsing course and multifactorial etiology. IBDs are usually considered to be a systemic illness, often involve other organs (6–47 %, principally skin, eyes, joints and hepatobiliary system). There are only sporadic reports of neurological manifestation in IBD patients (3–19 %, cerebrovascular disease, polyneuropathy, myopathy, and demyelinating disease including multiple sclerosis) and MRI studies have shown clinical non apparent cerebral demyelination in these patients. The cause of demyelination in IBD patients has not been explained yet.
Aim:
To draw attention to less common potentially serious illness of central nervous system in patients with IBD.
Methods:
We report on several cases of children with focal brain demyelination at the time of diagnosis Crohn’s disease and with neurological symptomatology in two of them. Two patients were treated by infliximab without worsening neurological symptomatology. No of them has developed demyelinating disease.
Conclusion:
Neurological disorders in IBD patients are less common but potentially severe. We point out the importance of an increased awareness for this problem, particularly in anti- TNFα-era.
Key words:
demyelination, Crohn’s disease, extraintestinal manifestation, anti-TNFα
Zdroje
1. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129: 819–826.
2. de Lau LML, de Vries JM, van der Woude CJ, et al. Acute CNS white matter lesions in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15 (4): 576–580.
3. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestation and complication in inflammatory bowel disease. World J Gastroenterol 2006; 14 (12): 4819–4831.
4. Lossos A, River Y, Eliakim A, Steiner I. Neurologic aspects of inflammatory bowel disease. Neurology 1995; 45: 416–421.
5. Oliveira GR, Teles BCV, Brasil ÉF, et al. Peripheral neuropathy and neurological disorders in an unselected Brazilian population – based cohort of IBD patients. Inflamm Bowel Dis 2008; 14: 389–395.
6. Benavente L, Moris G. Neurologic disorders associated with inflammatory bowel disease. Eur J Neurol 2011; 18: 138–143.
7. Rajendra S, Kadir ZA, Karim N, Zain Z. Ulcerative colitis and motor neurone disease: causal or coincidental? Singapore Med 2003; 44: 423–425.
8. Elsehety A, Bertorinin TE. Neurologic and neuropsychiatric complications of Crohn’s disease. South Med J 1997; 90 (6): 606–610.
9. Pokorny CS, Beran RG, Pokorny MJ. Association between ulcerative colitis and multiple sclerosis. Internal Medicine Journal 2007; 37: 721–724.
10. Andersen NN, Caspersen S, Jess T, Munkholm P. Occurence of demyelinating diseases after anti-TNFα treatment of inflammtory bowel disease: A Danish Crohn colitis database study. Journal of Crohn’s and Colitis 2008; 2: 304–309.
11. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004; 22 (Suppl 35): S134–S140.
12. Fromont A, De Seze J, Fleury MC, et al. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009; 45: 55–57.
13. Dejaco C, Fertl E, Prayer D, et al. Symptomatic cerebral microangiopathy preceeding initial manifestation of ulcerative colitis. Digestive Diseases and Sciences 1996; 41 (9): 1807–1810.
14. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occuring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum 2001; 44 (12): 2862–2869.
15. Hesselink JR. Demyelinating diseases of the brain. http://spinwarp.ucsd. edu/neuroweb/ Text/br-840.htm.
16. Zois CD, Katsanos KH, Kosmidou M, et al. Neurologic manifestations in inflammatory bowel diseases: current knowledge and novel insights. J Crohn Colitis 2010; 4: 115–124.
17. Geissler A, Andus T, Roth M, et al. Focal white-matter lesions in brain of patients with inflammatory bowel disease. Lancet 1995;15 (346): 190–191.
18. Beyenburg S, Scheid B, Deckert-Schlüter M, et al. Chronic progressive leukoencephalopathy in adult celiac disease. Neurology 1998;50 (3): 820–822.
19. Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNFα) and demyelination revisited: An ongoing story. J Neuroimmunol 2011; 234: 1–6.
20. Freeman HJ, Flak B. Demyelination-like syndrome in Crohn’s disease after infliximab therapy. Can J Gastroenterol 2005; 19 (5): 313–316.
21. Lozeron P, Denier Ch, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66 (4): 490–497.
22. Tanno M, Nakamura I, Kobayashi S, et al. New-onset demyelination induced by infliximab therapy in two rheumatoid patients. Clin Rheumatol 2006; 25: 929–933.
23. van der Laken CJ, Lerns WF, van Soersbergen RM, et al. Paraplegia in a patient receiving anti–tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum 2003; 48 (1): 269–270.
24. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor α therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 2004; 10 (1): 28–31.
25. Cisternas M, Gutiérrez M, Jacobelli S. Successful rechallenge with a-tumor necrosis factor α for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. Arthritis Rheum 2002; 46 (11): 3107–3108.
26. Mohan N. Letter to the editor. Arthritis Rheum 2002; 46 (11): 3108–3109.
27. Jarand J, Zochodne DW, Martin LO, et al. Neurological complications of infliximab (case report). J Rheum 2006;33: 1018–1020.
28. Ziegner UHM, Kobayashi RH, Cunningham-Rundles Ch, et al. Progressive neurodegeneration in patients with primary immunodeficiency disease on IVIG treatment. Clin Immunol 2002; 102 (1): 19–24.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2012 Číslo Suppl 1
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Diagnosis and management of pediatric cataract
- Foreign body in the gastrointestinal tract – a case report and current diagnostic and therapeutic recommendations
- ECMO (Extracorporeal Membrane Oxygenation) in the therapy of respiration and circulation failure in newborns and children
- The folic acid and neural tube defects – from past to present